Macular Thickness and Visual Acuity in Diabetic Hypertensive Patients

NCT ID: NCT05209971

Last Updated: 2022-01-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-31

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, measurements of central macular thickness using optical coherence tomography along with examination of visual acuity by Snellen's chart in diabetic hypertensive patients will be done .

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

correlate relationship between optical coherence tomography changes and visual acuity in patients with type 2 diabetes and hypertension

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Macular Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

macular thickness and visual acuity

optical coherence tomography

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetic patients with hypertension .

Exclusion Criteria

* Patients with type 1 diabetes mellitus .
* Ocular disease ( such as high myopia , glaucoma ) .
* Patients with opacities in the media ( corneal opacities , dense cataract , vitreous hemorrhage ) .
* Systemic medication (Tamoxifen , Chloroquine , Canthaxanthine ) to avoid its effect on macular thickness .
* Central visual field defect that prevents fixation on OCT .
* Intraocular inflammation such as anterior or posterior uveitis .
* Refractive error greater than 6 diopter .
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sohag University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Raghda Abdelraheem Abdellah

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Raghda Abdelraheem, doctor

Role: PRINCIPAL_INVESTIGATOR

faculty of medicine

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gamal Abdelateef, professor

Role: CONTACT

01001244421

Alahmady Hamad, professor

Role: CONTACT

01111102698

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Soh-Med-22-01-05

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Myopic Macular Haemorrhages
NCT00345228 COMPLETED